VenPro

VenPro Corporation was a medical technology company specializing in the development of biological heart valves and vascular grafts for cardiovascular surgery. The company is best known for its flagship product, the Contegra pulmonary valved conduit, which utilized a glutaraldehyde-preserved bovine jugular vein to provide a ready-to-use alternative to human homografts. This innovation addressed the critical shortage of donor tissue and offered surgeons a flexible, hemodynamically efficient option for reconstructing the right ventricular outflow tract in both pediatric and adult patients. VenPro's technology significantly improved outcomes for patients with congenital heart defects by providing a durable and suturable biological solution. In 2001, the company was acquired by Medtronic, which integrated VenPro's products into its structural heart division to expand its leadership in the congenital heart disease market.